Yale Cancer Center and our partner, Smilow Cancer Hospital at Yale-New Haven, acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers. The latest performance data for breast center is listed below.
|Breast Measures||Expected Estimated Performance Rates (percentage)||Yale Performance 2011||Yale Performance 2012||Yale Performance 2013|
|Image or palpation-guided needle biopsy (core or FNA) of the primary site is performed to establish diagnosis of breast cancer (Quality Improvement)||80%||85.90||88.40||89.30|
|Tamoxifen or third generation aromotase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer (Accountability)||90%||93.30||93.50||92.50|
|Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes (Accountability||90%||92.30||91.30||90.30|
|Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability)||90%||94.70||96.20||95.40|
|Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer (Accountability)||90%||100.00||93.50||91.40|
**Higher percentage is better